miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7684-7692

  De Preter, Katleen ^a   Mestdagh, Pieter ^a   Vermeulen, Jöelle ^a   Zeka, Fjoralba ^a   Naranjo, Arlene ^b   Bray, Isabella ^c   Castel, Victoria ^d   Chen, Caifu ^f   Drozynska, Elzbieta ^g   Eggert, Angelika ^h   Hogarty, Michael D ⁱ   Iźycka Świeszewska, Ewa ^g   London, Wendy B ^j   Noguera, Rosa ^e   Piqueras, Marta ^e   Bryan, Kenneth ^c   Schowe, Benjamin ^k   Van Sluis, Peter ^l   Molenaar, Jan J ^l   Schramm, Alexander ^h   Schulte, Johannes H ^h   Stallings, Raymond L ^c   Versteeg, Rogier ^l   Laureys, Geneviève ^a   Van Roy, Nadine ^a   Speleman, Frank ^a   Vandesompele, Jo ^a   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF FLORIDA   (United States)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

^f APPLIED BIOSYSTEMS   (United States)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k TU DORTMUND UNIVERSITY   (Germany)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; PARAFFIN;

ARTICLE; CANCER RISK; CANCER SURVIVAL; CLASSIFIER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EXTERNAL VALIDITY; FROZEN SECTION; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROBLASTOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; RNA ANALYSIS; VALIDATION STUDY;

EID: 84055212052     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0610     Document Type: Article

References (26)

1. Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma. Dis Med 2010;10:29-36.
2. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10:663-71.
3. Vermeulen J, De Preter K, Lefever S, Nuytens J, De Vloed F, Derveaux S, et al. Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Res 2011;39:e63.
4. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67:976-83.
5. Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Can J Int du Cancer 2010;127:2374-85.
6. Wang WX, Wilfred BR, Baldwin DA, Isett RB, Ren N, Stromberg A, et al. Focus on RNA isolation: obtaining RNA for microRNA (miRNA) expression profiling analyses of neural tissue. Biochimica et biophysica acta 2008;1779:749-57.
7. Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F, et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008;36:e143.
8. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009;10:R64.
9. WillemsE, Leyns L, Vandesompele J. Standardization of real-timePCR gene expression data from independent biological replicates. Anal Biochem 2008;379:127-9.
10. Lefever S, Hellemans J, Pattyn F, Przybylski DR, Taylor C, Geurts R, et al. RDML: structured language and reporting guidelines for real-time quantitative PCR data. Nucleic Acids Res 2009;37:2065-9.
11. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72. (Pubitemid 34526173)
12. Ruschhaupt M, Huber W, Poustka A, Mansmann U. A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol 2004;3:Article 37.
13. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clinical cancer research: an official journal of the American Association for Can Res 2010;16:1532-41.
14. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. Plos One 2009;4:e7850.
15. Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010;127:2374-85.
16. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98:1193-203. (Pubitemid 44390990)
17. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8. (Pubitemid 46631411)
18. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28:3506-15.
19. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005;7:337-50. (Pubitemid 40544651)
20. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005;24:7902-12. (Pubitemid 41715196)
21. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Can Res 2004;64:6883-91. (Pubitemid 39330995)
22. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005;23:7332-41. (Pubitemid 46202346)
23. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5. (Pubitemid 44325933)
24. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. Plos One 2008;3:e2236.
25. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010;29:1394-404.
26. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.